Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Thoughts on Amazon –What Does Its Valuation Tells Us?

Netflix & Amazon Expand in Korea – Not a Coincidence

Okja: The Fight Between Netflix Vs. CJ CGV

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>Lepu Biopharma is a biotech spin-off of A-share listed Lepu Medical. The company is looking to raise up to USD 200 million via a Hong Kong listing.</li>
<li>We look at the company's core products, including HX008, LP002, MRG003 and MRG002. The products have their own differentiating factors to tackle the intense competition</li>
<li>We think the company management lack track record in drug development and investors are mostly domestic individuals and funds.</li>
</ul>


Lepu Biopharma is a biotech spin-off of A-share listed Lepu Medical. The company is looking to raise up to USD 200 million via a Hong Kong listing.
We look at the company's core products, including HX008, LP002, MRG003 and MRG002. The products have their own differentiating factors to tackle the intense competition
We think the company management lack track record in drug development and investors are mostly domestic individuals and funds.


Lepu Biopharma (乐普生物科技) Pre-IPO: Differentiation Strategy for Intense Competition